Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 11/20 | 0.67 |
| ▸ | SYK | P43405 | 11/20 | 0.67 |
| ▸ | SRC | P12931 | 10/20 | 0.67 |
| ▸ | CDK2 | P24941 | 5/20 | 0.67 |
| ▸ | AURKA | O14965 | 4/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 3/20 | 0.50 |
| ▸ | INSR | P06213 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14379008 | 0.85 | AURKA (0.60) | SYKSRCCDK2AURKAAURKB | |
| SCHEMBL6978008 | 0.82 | CDK2 (0.60) | ZAP70CDK2AURKAAURKBINSR | |
| SCHEMBL14216016 | 0.81 | ZAP70 (0.72) | ZAP70SYKSRCCDK2AURKA | |
| SCHEMBL14216122 | 0.81 | ZAP70 (1.00) | ZAP70SYKSRCCDK2AURKA | |
| SCHEMBL14216149 | 0.78 | SYK (0.68) | ZAP70SYKSRCCDK2CDK4 | |
| SCHEMBL14216117 | 0.78 | SYK (0.69) | ZAP70SYKSRCCDK2AURKA | |
| SCHEMBL13924509 | 0.76 | SYK (1.00) | ZAP70SYKSRCCDK2 | |
| SCHEMBL14216203 | 0.76 | SYK (0.77) | ZAP70SYKSRCCDK2AURKA | |
| SCHEMBL14216198 | 0.76 | ZAP70 (0.77) | ZAP70SYKSRCCDK2AURKA | |
| SCHEMBL14216024 | 0.76 | ZAP70 (0.77) | ZAP70SYKSRCCDK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605946-B1 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1605946-B1 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7276502-B2 | Thiazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276502-B2 | Thiazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276502-B2 | Thiazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1605946-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050004150-A1 | For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| WO-2004087699-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004150-A1 | For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders | TSLP, JAK1, SERPINB1 | ZAP70 82/4885SYK 463/4885SRC 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.